Scribe Therapeutics Inc.

NASDAQ:SCTX

Biotechnology

Healthcare
$15.77 -4.80%

-$0.91 today

Market cap
$255.19M
Beta
0.00

Volume 0.27M

Average 0.98M

Returns on capital

Scribe Therapeutics Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

No return metrics data available.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Benjamin L. Oakes

Co-Founder, President, CEO & ChairmanUSD 574.98K37264.78K1.64%

David L. Parrot

CFO & TreasurerUSD 475.83K57——

Svetlana Lucas

Chief Operating OfficerUSD 466.98K543.00K0.02%

Jennifer A. Doudna

Co-Founder & Scientific Advisor—620<0.01%

David F. Savage

Co-Founder & Scientific Advisor————

Brett T. Staahl

Co-Founder & VP of External Innovation————

George Manning

VP & Controller————

Richard Hector

Head of Intellectual Property————

Sunny Mok

Senior Vice President of Operations————

Chitra Sharma

Senior Vice President of Development————

Stephen V. Thau

Secretary————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 27, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

8

$71.32M

Sells

0

$0.00

Net Transaction Value

+$71.32M

Net buying

Most Active

Aghazadeh Behzad

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jul 28, 26

Aghazadeh Behzad

Indirect

Buy$144.3K
Jul 27, 26

AH Bio Fund II, L.P.

Indirect

Buy$5M
Jul 27, 26

GORDON CARL L

Indirect

Buy$15M
Jul 27, 26

ORBIMED ADVISORS LLC

Indirect

Buy$15M
Jul 24, 26

Aghazadeh Behzad

Indirect

Buy$1.1M
Jul 24, 26

Aghazadeh Behzad

Indirect

Buy$35M
Jul 23, 26

Lucas Svetlana

Indirect

Buy$45K
Jul 23, 26

Parrot David

Indirect

Buy$20K

Summary

Insiders reported 8 buys worth $71.32M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $71.32M. Aghazadeh Behzad was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

No growth data available

Competitors

Who does Scribe Therapeutics Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Competitors

Peer companies in the same sector

Health

No competitor data available.

Questions

Management questions

Common questions about SCTX's management, answered from reported figures.

Who manages SCTX?

Scribe Therapeutics Inc. (SCTX) lists 11 active executives. The top listed executive is Benjamin L. Oakes, Co-Founder, President, CEO & Chairman.

Are SCTX insiders buying or selling?

Recent insider activity shows net buying of $90.46M.